Bliss GVS Pharma Q1 FY27 Results (NSE: BLISSGVS)
Signal: Margins at cyclical peak
The read
The key inflection is the consolidated EBITDA-margin rebound to 30.1% from approximately 21.6% in Q4FY26, but the trajectory remains mixed because margin was 37.0% in the year-ago quarter and EBITDA growth of 12.0% materially lagged revenue growth of 37.6%; the parent was stronger, with standalone EBITDA margin up 110bps YoY and PAT up 83.5%.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹285.58 Cr | 37.6% | +11.1% |
| EBIT | ₹76.06 Cr | 10.9% | |
| Net profit | ₹50.1 Cr | 16.4% | |
| EPS | ₹4.73 | 15.9% | |
| EBIT margin | 30.1% |
P&L walk
Consolidated revenue accelerated to ₹28,557.56 lakh, +37.6% YoY and +11.1% QoQ, but EBITDA grew only +12.0% because the comparison included unusually high year-ago profitability; the QoQ margin recovery to 30.1% was aided by sharply lower finance costs and other income did not materially distort PAT.
Segments
No segment split is disclosed because the Group reports a single operating segment, Pharmaceutical and Healthcare; however, consolidated revenue of ₹28,557.56 lakh exceeded standalone revenue of ₹22,158.51 lakh by ₹6,399.05 lakh, while consolidated PAT attributable to owners of ₹5,010 lakh exceeded standalone PAT of ₹3,861.77 lakh by ₹1,148.23 lakh, showing a material subsidiary contribution.
Key positives
- Consolidated revenue reached ₹28,557.56 lakh, growing +37.6% YoY and +11.1% QoQ, marking a clear acceleration from +3.8% YoY in Q3FY26.
- Standalone EBITDA rose +39.8% YoY to approximately ₹6,063 lakh and margin expanded 110bps YoY to 27.4%, showing stronger parent-level operating execution.
- Finance costs fell 89.4% YoY to ₹57.94 lakh on a consolidated basis, supporting the 35.4% QoQ increase in PAT attributable to owners.
- Standalone gross margin expanded approximately 280bps YoY to 59.0%, indicating better material-cost absorption at the parent level.
Key concerns
- Consolidated EBITDA grew only +12.0% YoY against revenue growth of +37.6%, with EBITDA margin compressing approximately 690bps from the unusually high 37.0% year-ago level.
- Consolidated employee expense rose +38.9% YoY to ₹4,304.72 lakh and included ₹297.04 lakh of ESOP expense, increasing employee cost to approximately 15.1% of revenue.
- Consolidated PAT growth of +16.4% trailed revenue growth because the EBITDA margin remained below the year-ago base and other income fell 72.9% YoY to ₹959.97 lakh.
Research and educational content only. Not investment advice.